CRMD Earnings Date: Nov 11, 2026 (Estimated) — CorMedix Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CRMD's next earnings date?
CorMedix Inc. (CRMD) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.11 on revenue of $52.9M.
How did CRMD do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), CorMedix Inc. posted EPS of $0.29 versus the $0.24 estimate, a beat of 20.8%. Revenue was $101.9M against a $96.0M estimate. The stock's 1-day post-earnings move was +14.6%.
How much does CRMD stock move after earnings?
CRMD beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.0% (up or down) in the day after earnings.
About CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | 0.24 | 0.29 | +20.83% | $101.9M | ✅ Beat | +14.65% | +20.00% | +10.21% |
| 2026-05-14 | Q1 2026 | 0.33 | 0.43 | +30.30% | $127.4M | ✅ Beat | +5.73% | +5.73% | +16.53% |
| 2026-03-05 | Q4 2025 | 0.83 | 0.61 | -26.51% | $128.6M | ❌ Miss | -11.52% | -6.04% | -0.98% |
| 2025-11-12 | Q3 2025 | 0.57 | 0.57 | +0.00% | $104.3M | ➖ Inline | +2.06% | -9.96% | +4.92% |
| 2025-03-25 | Q4 2024 | 0.14 | 0.22 | +57.14% | $31.2M | ✅ Beat | -31.85% | -42.80% | -21.54% |
| 2024-08-14 | Q2 2024 | -0.25 | -0.25 | +0.00% | $806,119 | ➖ Inline | +30.16% | +32.80% | +81.48% |
| 2024-05-09 | Q1 2024 | -0.28 | -0.25 | +10.71% | $0 | ✅ Beat | -5.17% | -7.98% | -9.55% |
| 2024-03-12 | Q4 2023 | -0.20 | -0.26 | -30.00% | $0 | ❌ Miss | -2.84% | +7.95% | +50.00% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $101.9M total
| Segment | Share | Revenue | YoY | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|
| Product | 92.6% | $94.3M | — | $202.8M | $121.9M | $94.3M |
| Contract Revenue | 4.9% | $5.0M | — | — | $5.5M | $5.0M |
| Grant Income | 2.6% | $2.6M | — | — | — | $2.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.